News
Tag: Company Updates
-
Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
BOTHELL, Washington and VANCOUVER, British Columbia, Jan. 24, 2018 /PRNewswire/ — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an amendment to their Technology Licence Agreement with the University of Bristol, United Kingdom. Achieve has been granted exclusive rights for…
-
Achieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking Cessation
BOTHELL, Wash and VANCOUVER, British Columbia, Nov. 28, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an agreement with Auckland UniServices Limited, as the commercial arm of the University of Auckland, to provide cytisine for use in…
-
Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine
BOTHELL, Wash and VANCOUVER, British Columbia, Oct. 26, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced it has entered into an exclusive supply agreement with Sopharma AD (BSE: 3JR, WSE: SPH) for the manufacture of cytisine active…
-
Achieve Life Sciences Announces Closing of Merger with OncoGenex Pharmaceuticals
Commences Trading on NASDAQ Capital Market on August 3, 2017 Under Ticker Symbol “ACHV” BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 1, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced the closing of its previously announced merger with OncoGenex Pharmaceuticals, as a result of which the stockholders of Achieve have become the majority…
-
Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC
June 13, 2017. Special Meeting of OncoGenex Stockholders to Vote on Proposed Merger Scheduled for August 1, 2017. MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, June 13, 2017 /CNW/ — Achieve Life Sciences, Inc. (Achieve) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (OncoGenex) today announced that the Registration Statement on Form S-4 has been…